These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 36409282)

  • 1. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
    Rakmanotham A; Moonla C; Sosothikul D
    Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis.
    Srichumpuang C; Rakmanotham A; Moonla C; Sosothikul D
    Orphanet J Rare Dis; 2024 Mar; 19(1):135. PubMed ID: 38532451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics.
    Nummi V; Lehtinen AE; Iorio A; Szanto T; Lassila R
    Haemophilia; 2022 Nov; 28(6):e237-e244. PubMed ID: 35939628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: Lessons learned with the CHO-KLAT tool.
    Carcao M; Zunino L; Young NL; Dover S; Bouskill V; Hilliard P; Price VE; Blanchette VS
    Haemophilia; 2020 Jan; 26(1):73-78. PubMed ID: 31865620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical application of extended half-life factor VIII in children with severe haemophilia A.
    Dettoraki A; Michalopoulou A; Mazarakis M; Saslis S; Stamati I; Kapsimali Z; Pergantou H
    Haemophilia; 2022 Jul; 28(4):619-624. PubMed ID: 35503081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States.
    Aledort L; Milligan S; Watt M; Booth J
    J Manag Care Spec Pharm; 2020 Apr; 26(4):492-503. PubMed ID: 32223610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Australian experience with switching to extended half-life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation.
    Brennan Y; Parikh S; McRae S; Tran H
    Haemophilia; 2020 May; 26(3):529-535. PubMed ID: 32243027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Break-through bleeding in relation to pharmacokinetics of Factor VIII in paediatric patients with severe haemophilia A.
    Cheng X; Li P; Chen Z; Zhang N; Zhen Y; Zhao L; Wang X; Wu R
    Haemophilia; 2018 Jan; 24(1):120-125. PubMed ID: 29194866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efmoroctocog Alfa: A Review in Haemophilia A.
    Frampton JE
    Drugs; 2021 Nov; 81(17):2035-2046. PubMed ID: 34743314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in clinical outcomes and replacement factor VIII use in patients with haemophilia A after factor VIII pharmacokinetic-guided prophylaxis based on Bayesian models with myPKFiT
    Mingot-Castellano ME; Parra R; Núñez R; Martorell M
    Haemophilia; 2018 Sep; 24(5):e338-e343. PubMed ID: 30028549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients.
    Megías-Vericat JE; Bonanad S; Haya S; Cid AR; Marqués MR; Ferrada A; Monte-Boquet E; Pérez-Alenda S; Bosch P; Querol-Giner F; Poveda JL
    Thromb Res; 2021 Sep; 205():99-105. PubMed ID: 34293540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of simoctocog alfa versus extended half-life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching-adjusted indirect comparison method.
    Kessler CM; Corrales-Medina FF; Mannucci PM; Jiménez-Yuste V; Tarantino MD
    Eur J Haematol; 2023 Nov; 111(5):757-767. PubMed ID: 37587687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
    Chowdary P; Mullins ES; Konkle BA; McGuinn C; Park YS; Stasyshyn O; Zulfikar B; Engl W; Tangada S
    Haemophilia; 2020 Jul; 26(4):e168-e178. PubMed ID: 32597029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
    Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
    Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A.
    Huang K; Zhen Y; Li G; Wu X; Chen Z; Wu R
    Haemophilia; 2021 Jul; 27(4):e450-e457. PubMed ID: 34015176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient powered prophylaxis: A 12-month study of individualized prophylaxis in adults with severe haemophilia A.
    Sun HL; McIntosh KA; Squire SJ; Yang M; Bartholomew C; Gue DS; Camp PG; Jackson SC
    Haemophilia; 2017 Nov; 23(6):877-883. PubMed ID: 28851133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspective - The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021.
    Di Minno A; Spadarella G; Esposito S; Mathew P; Di Minno G; Mannucci PM
    Blood Rev; 2021 Nov; 50():100849. PubMed ID: 34024681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PK-guided personalized prophylaxis with Nuwiq
    Lissitchkov T; Rusen L; Georgiev P; Windyga J; Klamroth R; Gercheva L; Nemes L; Tiede A; Bichler J; Knaub S; Belyanskaya L; Walter O; Pasi KJ
    Haemophilia; 2017 Sep; 23(5):697-704. PubMed ID: 28452151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada.
    Matino D; Germini F; Chan AKC; Decker K; Iserman E; Chelle P; Edginton AN; Oladoyinbo O; Trinari E; Keepanasseril A; Iorio A
    Haemophilia; 2024 Mar; 30(2):345-354. PubMed ID: 38379181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience.
    Tagliaferri A; Matichecchia A; Rivolta GF; Riccardi F; Quintavalle G; Benegiamo A; Rossi R; Coppola A
    Blood Transfus; 2020 Sep; 18(5):374-385. PubMed ID: 31855153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.